<DOC>
	<DOCNO>NCT01186861</DOCNO>
	<brief_summary>A multicenter , randomize , double-blind , placebo-controlled , phase 2 study 1:1 randomization scheme .</brief_summary>
	<brief_title>Phase 2 Study Maintenance OSI-906 Plus Erlotinib ( Tarceva® ) , Placebo Plus Erlotinib Patients With Nonprogression Following 4 Cycles Platinum-based Chemotherapy</brief_title>
	<detailed_description>Adult patient advance Non-small Cell Lung Cancer ( NSCLC ) nonprogression platinum-based chemotherapy randomize 1:1 receive either OSI-906 plus erlotinib placebo plus erlotinib .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirm locally advanced metastatic stage IIIB IV NSCLC Have experience Complete Response ( CR ) , Partial Response ( PR ) Stable Disease ( SD ) follow completion 4 cycle firstline platinumbased chemotherapy progress time entry study ( prior complete firstline combination bevacizumab therapy permit ; however , current use maintenance bevacizumab permit . A maximum interval 28 day last day treatment cycle randomization Patient recover prior chemotherapyrelated toxicity ≤ grade 2 EGFR mutation status must confirm participation study . EGFR analysis perform either central local laboratory . If analysis do locally , verifiable documentation confirm EGFR mutation status must submit review approval APGD prior randomization . If local result available , formalinfixed , paraffinembedded archival tissue representative tumor absence archival tissue , fresh tumor tissue sample sufficient size perform EGFR mutation analysis must submit centrally . Results central analysis must available prior randomization . Additionally , subject provide tissue block centrally biomarker analysis whenever possible . Ideal tissue requirement : block ≥5 mm2 tumor area sufficient provide four 4micron , five 10micron section ) Measurable disease ( patient PR SD firstline platinumbased chemotherapy ) accord Response Evaluation Criteria Solid Tumors ( RECIST ) ( version 1.1 ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 Previous adjuvant neoadjuvant treatment permit Must able take oral medication Fasting glucose ≤ 150 mg/dL ( 8.3 mmol/L ) . Concurrent use noninsulinotropic antihyperglycemic therapy permit dose stable ≥ 4 week time randomization Adequate hematopoietic , hepatic , renal function define follow : Neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Bilirubin ≤ 1.5 x Upper Limit Normal ( ULN ) AST ALT ≤ 2.5 x ULN , ≤ 5 x ULN patient document liver metastasis Serum creatinine ≤ 1.5 x ULN Potassium , magnesium calcium within normal limit ( supplementation retesting permit ) Female patient must either : Of non child bear potential : postmenopausal ( define least 1 year without menses ) prior Screening , document surgically sterile status post hysterectomy ( least 1 month prior Screening ) Or , childbearing potential : must negative urine pregnancy test Screening , must use two form birth control ( one must barrier method ) start Screening throughout study period 30 day final study drug administration Female patient must breastfeed Screening study period 30 day final study drug administration Female patient must donate ovum start Screening throughout study period 30 day final study drug administration Male patient female spouse/partners childbearing potential must use highly effective contraception consist two form birth control ( one must barrier method ) start Screening continue throughout study period 30 day final study drug administration Male patient must donate sperm start Screening throughout study period least 30 day final study drug administration Prior radiation therapy permit provided patient recover acute toxic effect radiotherapy prior randomization . A minimum 28 day must elapse end radiotherapy randomization Prior surgery permit provide surgery perform 21 day prior randomization adequate wound heal occur prior randomization Patients must provide write ( sign ) inform consent participate study use tumor tissue Prior exposure agent direct Human Epidermal Receptor ( HER ) axis ( eg , erlotinib , gefitinib , cetuximab , trastuzumab ) Malignancies NSCLC within past 3 year ( exception curatively treat : basal squamous cell carcinoma skin ; locally advanced prostate cancer ; ductal carcinoma situ breast ; situ cervical carcinoma ; superficial bladder cancer ) Type 1 diabetes mellitus Type 2 diabetes mellitus currently require insulinotropic insulin therapy Prior insulinlike growth factor receptor ( IGF1R ) Prior investigational agent within 21 day prior randomization Concurrent use maintenance bevacizumab History poorly control gastrointestinal disorder could affect absorption study drug ( eg , Crohn 's disease , ulcerative colitis , etc ) History ( within last 180 day ) significant cardiovascular disease unless disease wellcontrolled . Significant cardiac disease include second/third degree heart block ; clinically significant ischemic heart disease ; superior vena cava ( SVC ) syndrome ; poorly control hypertension ; congestive heart failure New York Heart Association ( NYHA ) Class II worse ( slight limitation physical activity ; comfortable rest , ordinary physical activity result fatigue , palpitation , dyspnea ) History arrhythmia ( multifocal premature ventricular contraction [ PVCs ] , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) symptomatic require treatment ( ≥ grade 3 ) , leave bundle branch block ( LBBB ) , asymptomatic sustain ventricular tachycardia allow . Patients atrial fibrillation control medication exclude Mean QTcF interval &gt; 450 msec base independent central reviewer analysis screen visit ECGs Use drug know risk cause Torsades de Pointes ( TdP ) prohibit within 14 day prior randomization Use potent CYP1A2 inhibitor ciprofloxacin fluvoxamine . Other less potent CYP1A2 inhibitors/inducers exclude Use potent CYP3A4 inhibitor ketoconazole , clarithromycin , atazanavir , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , troleandomycin ( TAO ) , voriconazole Use proton pump inhibitor omeprazole . Use H2receptor antagonists ranitidine exclude History cerebrovascular accident ( CVA ) within 180 day prior randomization result ongoing neurologic instability Active infection , serious underlie medical condition ( include type active seizure disorder within 12 month prior randomization ) , serious chronic illness would impair ability patient receive study drug History psychiatric neurologic condition might impair patient 's ability understand comply requirement study provide inform consent Pregnant breastfeeding female Symptomatic brain metastasis stable , require steroid , require radiation and/or relate treatment ( e.g. , antiepileptic medication ) within 21 day prior randomization History allergic reaction attribute compound similar chemical biologic composition study drug Participated interventional clinical study treat investigational drug within 30 day 5 half life whichever longer , prior initiation Screening course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>OSI-906</keyword>
	<keyword>Placebo</keyword>
	<keyword>Platinum-based chemotherapy</keyword>
</DOC>